“…Notably, a few of the ligands have already entered preclinical or clinical trials, among which quarfloxin (CX-3543) has entered phase 2 clinical trials (Bates et al, 2007). Considering the importance of G4 and its ligands, our team has carried out a series of research in this area (Sun et al, 2006(Sun et al, , 2007(Sun et al, , 2009Zhou et al, 2008bZhou et al, , 2009Li et al, 2009;Yang et al, 2009Yang et al, , 2010aYang et al, , 2010bYang et al, , 2010cTian et al, 2010;Yang and Okamoto, 2010;Zhang et al, 2010;Ji et al, 2011aJi et al, , 2011b.…”